Scott D. Lane, Lokesh R. Shahani, Rodrigo Machado-Vieira, Jair C. Soares
{"title":"大麻与其他药物滥用的回顾性研究:与重症精神病住院患者 30 天再入院和功能全面评估的关系","authors":"Scott D. Lane, Lokesh R. Shahani, Rodrigo Machado-Vieira, Jair C. Soares","doi":"10.1016/j.psycom.2024.100167","DOIUrl":null,"url":null,"abstract":"<div><p>Substance misuse in individuals with psychiatric disorders is associated with worsening symptoms and hospitalization. The present retrospective, observational study analyzed inpatient psychiatry hospital EHR data from 2013 to 2020 (N = 12,742) in patients with co-occurring psychiatric disorders and substance misuse. Substance use was categorized as cannabis-only, alcohol-only, or illicit/poly-substance. Two outcome variables were evaluated using multiple-regression: (1) Global Assessment of Functioning (GAF) Score at admission, and (2) 30-day readmission rate. Covariates included primary Axis I disorder, living situation, Race/Ethnicity, education, sex, age, and total same-hospital readmissions (>30 days). Controlling for all covariates, the cannabis-only group had (1) significantly higher GAF score at admission (less severity) vs. both other groups; and (2) lower 30-day readmission rates vs. the illicit/poly-substance use group only. Post-hoc analyses revealed the results for the cannabis-only group vs. other drug use groups were robust, holding across all primary psychiatric diagnoses. Study limitations included lack of formal SUD diagnosis, lack of information in the EHR to quantify substance use patterns, retrospective study design, and lack of data to examine an appropriate psychiatric inpatient group free of substance misuse. Results are discussed in terms of the putative therapeutic efficacy of THC and cannabidiol on modulation of sleep, anxiety, and agitation.</p></div>","PeriodicalId":74595,"journal":{"name":"Psychiatry research communications","volume":"4 2","pages":"Article 100167"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772598724000138/pdfft?md5=b6dc31ce745331e200a5ce752e024ce3&pid=1-s2.0-S2772598724000138-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Retrospective examination of cannabis vs. other substance misuse: Associations with 30-day readmission and global assessment of functioning in hospitalized patients with serious mental illness\",\"authors\":\"Scott D. Lane, Lokesh R. Shahani, Rodrigo Machado-Vieira, Jair C. Soares\",\"doi\":\"10.1016/j.psycom.2024.100167\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Substance misuse in individuals with psychiatric disorders is associated with worsening symptoms and hospitalization. The present retrospective, observational study analyzed inpatient psychiatry hospital EHR data from 2013 to 2020 (N = 12,742) in patients with co-occurring psychiatric disorders and substance misuse. Substance use was categorized as cannabis-only, alcohol-only, or illicit/poly-substance. Two outcome variables were evaluated using multiple-regression: (1) Global Assessment of Functioning (GAF) Score at admission, and (2) 30-day readmission rate. Covariates included primary Axis I disorder, living situation, Race/Ethnicity, education, sex, age, and total same-hospital readmissions (>30 days). Controlling for all covariates, the cannabis-only group had (1) significantly higher GAF score at admission (less severity) vs. both other groups; and (2) lower 30-day readmission rates vs. the illicit/poly-substance use group only. Post-hoc analyses revealed the results for the cannabis-only group vs. other drug use groups were robust, holding across all primary psychiatric diagnoses. Study limitations included lack of formal SUD diagnosis, lack of information in the EHR to quantify substance use patterns, retrospective study design, and lack of data to examine an appropriate psychiatric inpatient group free of substance misuse. Results are discussed in terms of the putative therapeutic efficacy of THC and cannabidiol on modulation of sleep, anxiety, and agitation.</p></div>\",\"PeriodicalId\":74595,\"journal\":{\"name\":\"Psychiatry research communications\",\"volume\":\"4 2\",\"pages\":\"Article 100167\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2772598724000138/pdfft?md5=b6dc31ce745331e200a5ce752e024ce3&pid=1-s2.0-S2772598724000138-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychiatry research communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772598724000138\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatry research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772598724000138","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
精神疾病患者滥用药物与症状恶化和住院治疗有关。本项回顾性观察研究分析了 2013 年至 2020 年精神科住院患者的电子病历数据(N = 12742),研究对象为同时患有精神障碍和药物滥用的患者。药物使用分为纯大麻、纯酒精或非法/混合药物。采用多元回归法评估了两个结果变量:(1)入院时的功能全面评估(GAF)得分;(2)30 天再入院率。协变量包括主要轴 I 障碍、生活状况、种族/民族、教育程度、性别、年龄和同院再入院总次数(30 天)。在控制了所有协变量后,纯大麻组(1)与其他两组相比,入院时的 GAF 得分明显更高(严重程度更低);(2)与仅使用非法/多元物质组相比,30 天再入院率更低。事后分析表明,仅使用大麻组与其他药物使用组相比,结果是稳健的,在所有主要精神病诊断中都是如此。研究的局限性包括缺乏正式的 SUD 诊断、电子病历中缺乏量化药物使用模式的信息、研究设计具有回顾性,以及缺乏数据来检查无药物滥用的适当精神病住院患者群体。研究结果从 THC 和大麻二酚对调节睡眠、焦虑和躁动的假定疗效角度进行了讨论。
Retrospective examination of cannabis vs. other substance misuse: Associations with 30-day readmission and global assessment of functioning in hospitalized patients with serious mental illness
Substance misuse in individuals with psychiatric disorders is associated with worsening symptoms and hospitalization. The present retrospective, observational study analyzed inpatient psychiatry hospital EHR data from 2013 to 2020 (N = 12,742) in patients with co-occurring psychiatric disorders and substance misuse. Substance use was categorized as cannabis-only, alcohol-only, or illicit/poly-substance. Two outcome variables were evaluated using multiple-regression: (1) Global Assessment of Functioning (GAF) Score at admission, and (2) 30-day readmission rate. Covariates included primary Axis I disorder, living situation, Race/Ethnicity, education, sex, age, and total same-hospital readmissions (>30 days). Controlling for all covariates, the cannabis-only group had (1) significantly higher GAF score at admission (less severity) vs. both other groups; and (2) lower 30-day readmission rates vs. the illicit/poly-substance use group only. Post-hoc analyses revealed the results for the cannabis-only group vs. other drug use groups were robust, holding across all primary psychiatric diagnoses. Study limitations included lack of formal SUD diagnosis, lack of information in the EHR to quantify substance use patterns, retrospective study design, and lack of data to examine an appropriate psychiatric inpatient group free of substance misuse. Results are discussed in terms of the putative therapeutic efficacy of THC and cannabidiol on modulation of sleep, anxiety, and agitation.